LATIGO BIOTHERAPEUTICS INC

Latigo Biotherapeutics falls 9.35% to $15.02—market cap $995.8M, 200‑day SMA $19.33, and a resilient rare‑disease pipeline that may spark a rebound.

Latigo Biotherapeutics shares up 7.15% to $16.93 as board move fuels investor interest in its non‑opioid pain drug strategy.

Latigo Biotherapeutics (LTGO) stock up 6.64% today, trading at $16.34 with a $948M cap. Explore its recent 27‑day decline, 200‑day SMA, and 52‑week range.